KR20050053046A - 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 - Google Patents
항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 Download PDFInfo
- Publication number
- KR20050053046A KR20050053046A KR1020050044060A KR20050044060A KR20050053046A KR 20050053046 A KR20050053046 A KR 20050053046A KR 1020050044060 A KR1020050044060 A KR 1020050044060A KR 20050044060 A KR20050044060 A KR 20050044060A KR 20050053046 A KR20050053046 A KR 20050053046A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- hot water
- sample
- effect
- mixed
- Prior art date
Links
- 230000004792 oxidative damage Effects 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title abstract description 47
- 238000011084 recovery Methods 0.000 title abstract description 23
- 206010028980 Neoplasm Diseases 0.000 title description 38
- 201000011510 cancer Diseases 0.000 title description 38
- 238000002360 preparation method Methods 0.000 title description 7
- 230000005764 inhibitory process Effects 0.000 title description 5
- 210000000987 immune system Anatomy 0.000 title description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000000284 extract Substances 0.000 claims abstract description 86
- 230000000694 effects Effects 0.000 claims abstract description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 150000004676 glycans Chemical class 0.000 claims abstract description 43
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 43
- 239000005017 polysaccharide Substances 0.000 claims abstract description 43
- 241000125175 Angelica Species 0.000 claims abstract description 26
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 26
- 239000002244 precipitate Substances 0.000 claims abstract description 15
- 208000018706 hematopoietic system disease Diseases 0.000 claims abstract description 4
- 208000026278 immune system disease Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000000513 bioprotective effect Effects 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 abstract description 33
- 230000001093 anti-cancer Effects 0.000 abstract description 18
- 230000001737 promoting effect Effects 0.000 abstract description 17
- 230000001590 oxidative effect Effects 0.000 abstract description 7
- 238000011394 anticancer treatment Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000003412 degenerative effect Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 124
- 239000000523 sample Substances 0.000 description 94
- 230000005855 radiation Effects 0.000 description 39
- 230000006870 function Effects 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 34
- 210000002865 immune cell Anatomy 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 24
- 230000005880 cancer cell killing Effects 0.000 description 20
- 210000004698 lymphocyte Anatomy 0.000 description 19
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 18
- 229940104230 thymidine Drugs 0.000 description 18
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 239000011651 chromium Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 210000002536 stromal cell Anatomy 0.000 description 12
- 210000000601 blood cell Anatomy 0.000 description 11
- 239000002031 ethanolic fraction Substances 0.000 description 11
- 230000036737 immune function Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 239000002032 methanolic fraction Substances 0.000 description 10
- 210000000822 natural killer cell Anatomy 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 210000004988 splenocyte Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 9
- 229910052804 chromium Inorganic materials 0.000 description 9
- 241000411851 herbal medicine Species 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000002798 bone marrow cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 229910052722 tritium Inorganic materials 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 231100000277 DNA damage Toxicity 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 231100000244 chromosomal damage Toxicity 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000005931 immune cell recruitment Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002570 interstitial cell Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- -1 CSF) Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000005365 aminothiol group Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000006318 protein oxidation Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000703769 Culter Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 229960003190 adenosine monophosphate Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 231100000170 comet assay Toxicity 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
- 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물; 및 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물에 에탄올을 가하여 생성된 침전물인 다당체분획물을 유효성분으로 포함하는, 항암 치료용 약학적 조성물.
- 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물; 및 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물에 에탄올을 가하여 생성된 침전물인 다당체분획물을 유효성분으로 포함하는, 면역기능 증강용 약학적 조성물.
- 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물; 및 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물에 에탄올을 가하여 생성된 침전물인 다당체분획물을 유효성분으로 포함하는, 조혈기능 증진용 약학적 조성물.
- 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물; 및 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물에 에탄올을 가하여 생성된 침전물인 다당체분획물을 유효성분으로 포함하는, 산화적 손상에 대한 생체방호용 약학적 조성물.
- 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물; 및 동일 무게 비율로 혼합된 당귀, 천궁 및 백작약의 열수추출물에 에탄올을 가하여 생성된 침전물인 다당체분획물을 유효성분으로 포함하는, 항암제 또는 방사선 치료시 발생하는 면역 및 조혈기능 장해, 또는 산화적 손상에 의한 항암 치료 부작용 방지용 약학적 조성물.
- 제 1항 내지 제 5항 중 어느 한 항에 있어서, 상기 약학적 조성물에 포함되어 있는 다당체 분획물의 총량은, 상기 열수추출물에 포함되어 있는 다당체분획물의 양에 대하여 1.5 ~ 4배의 양인 것을 특징으로 하는 약학적 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0044060A KR100506396B1 (ko) | 2005-05-25 | 2005-05-25 | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0044060A KR100506396B1 (ko) | 2005-05-25 | 2005-05-25 | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0021746A Division KR100506384B1 (ko) | 2003-04-07 | 2003-04-07 | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050053046A true KR20050053046A (ko) | 2005-06-07 |
KR100506396B1 KR100506396B1 (ko) | 2005-08-10 |
Family
ID=37248804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2005-0044060A KR100506396B1 (ko) | 2005-05-25 | 2005-05-25 | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100506396B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101374536B1 (ko) * | 2011-06-10 | 2014-03-14 | 박혜림 | 곰보배추를 이용한 면역증강용 조성물 |
CN108367036A (zh) * | 2015-10-08 | 2018-08-03 | 韩国原子力研究院 | 制备具有提高的脂溶性多酚含量的草本组合物的方法、由此制备的草本组合物及其用途 |
WO2020067699A1 (ko) * | 2018-09-28 | 2020-04-02 | 콜마비앤에이치 주식회사 | 당귀 추출물, 천궁 추출물 및 작약 추출물을 포함하는 피로 개선 또는 운동 수행능력 증진용 조성물 |
KR20200036715A (ko) * | 2019-07-02 | 2020-04-07 | 콜마비앤에이치 주식회사 | 당귀 추출물, 천궁 추출물 및 작약 추출물을 포함하는 피로 회복 또는 운동 수행능력 증진용 조성물 |
KR20220154283A (ko) * | 2021-05-12 | 2022-11-22 | 주식회사 코시스바이오 | 면역기능 증진 활성이 있는 생약 유래 다당 분획물 및 이를 포함하는 조성물 |
-
2005
- 2005-05-25 KR KR10-2005-0044060A patent/KR100506396B1/ko active IP Right Grant
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101374536B1 (ko) * | 2011-06-10 | 2014-03-14 | 박혜림 | 곰보배추를 이용한 면역증강용 조성물 |
CN108367036A (zh) * | 2015-10-08 | 2018-08-03 | 韩国原子力研究院 | 制备具有提高的脂溶性多酚含量的草本组合物的方法、由此制备的草本组合物及其用途 |
US10736929B2 (en) | 2015-10-08 | 2020-08-11 | Korea Atomic Energy Research Institute | Method for preparing herbal composition having increased fat-solublepolyphenol content, herbal composition prepared thereby and use thereof |
CN108367036B (zh) * | 2015-10-08 | 2021-09-24 | 韩国原子力研究院 | 制备具有提高的脂溶性多酚含量的草本组合物的方法、由此制备的草本组合物及其用途 |
WO2020067699A1 (ko) * | 2018-09-28 | 2020-04-02 | 콜마비앤에이치 주식회사 | 당귀 추출물, 천궁 추출물 및 작약 추출물을 포함하는 피로 개선 또는 운동 수행능력 증진용 조성물 |
KR20200036715A (ko) * | 2019-07-02 | 2020-04-07 | 콜마비앤에이치 주식회사 | 당귀 추출물, 천궁 추출물 및 작약 추출물을 포함하는 피로 회복 또는 운동 수행능력 증진용 조성물 |
KR20220154283A (ko) * | 2021-05-12 | 2022-11-22 | 주식회사 코시스바이오 | 면역기능 증진 활성이 있는 생약 유래 다당 분획물 및 이를 포함하는 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR100506396B1 (ko) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100506384B1 (ko) | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 | |
Chatterjee et al. | Evaluation of antitumor activity of Cuscuta reflexa Roxb (Cuscutaceae) against Ehrlich ascites carcinoma in Swiss albino mice | |
CN101485655B (zh) | 二氢杨梅素在制备防治肿瘤放化疗不良反应的药物的应用 | |
Aminin et al. | Immunomodulatory properties of Cumaside | |
WO2003099309A1 (en) | Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits | |
KR100506396B1 (ko) | 항암, 면역 및 조혈 기능 증진 효과와 산화적 생체 손상의억제 효과를 갖는 생약조성물과 그 제조방법 | |
Han et al. | Activation of murine macrophage cell line RAW 264.7 by Korean propolis | |
Soni et al. | N-methyl-6, 7-dimethoxyisoquinolone in Annona squamosa twigs is the major immune modifier to elicit polarized Th1 immune response in BALB/c mice | |
George et al. | A polyherbal ayurvedic drug–Indukantha Ghritha as an adjuvant to cancer chemotherapy via immunomodulation | |
US20030044424A1 (en) | Novel immune enhancing compositions | |
CN109336987A (zh) | 一种羊肚菌和牛肝菌复方粗多糖及制备方法和医用用途 | |
Ramachandran et al. | Induction of apoptosis of azurin synthesized from P. áaeruginosa MTCC 2453 against Dalton's lymphoma ascites model | |
Subramoniam et al. | Inhibition of antigen-induced degranulation of sensitized mast cells by Trichopus zeylanicus in mice and rats | |
KR100440863B1 (ko) | 조혈기능 증진 및 방사선 방호용 생약추출물 | |
CN109602759A (zh) | 罗汉松实多糖的用途 | |
JP2010270104A (ja) | iNKT細胞活性化剤 | |
AU2007361007A1 (en) | Immunopotentiating composition from labisia pumila extract | |
Innih et al. | Effects of tetracarpidium conophorum on iron overload‐induced cardiac toxicity in Wistar rats | |
Alinezhad et al. | Assessing the protective effect of Primula heterochroma Stapf extracts against sodium fluoride-induced hemolysis in rat erythrocytes | |
KR100449655B1 (ko) | 조혈 및 면역기능 증강 및 방사선 방호용 기능성 식품 | |
KR20010100551A (ko) | 면역, 조혈기능 증진 및 방사선 방호용 생약조성물 및그의 제조방법 | |
KR100471580B1 (ko) | 뱀딸기 추출물 및 영지버섯 추출물 혼합물의 세포사멸증진제로서의 용도 | |
RU2208446C2 (ru) | Средство для профилактики заболеваний онкологического и неонкологического профиля и для коррекции нарушений гомеостаза | |
KR100857249B1 (ko) | 매생이 열수추출물을 함유하는 면역 활성 증가용 조성물 | |
KR20010089498A (ko) | 표고버섯 균사체 추출물을 함유하는 lak 활성스크리닝물질 및 이를 사용한 lak 활성스크리닝법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130607 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140703 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160607 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190626 Year of fee payment: 15 |